Actinogen Medical Limited ( (AU:ACW) ) has shared an announcement.
Actinogen Medical announced that its Chief Medical Officer, Dr. Dana Hilt, presented an academic poster at the International Conference on Alzheimer’s & Parkinson’s Diseases. The poster highlighted the benefits of Xanamem treatment in patients with elevated blood pTau181, a biomarker for Alzheimer’s Disease, and informed the design of a new phase 2b/3 trial. This trial, currently recruiting in Australia and the USA, aims to evaluate the efficacy of Xanamem in slowing Alzheimer’s progression. Interim results are expected in late 2025, with final results anticipated in 2026. This development positions Actinogen as a key player in the Alzheimer’s treatment landscape, potentially impacting stakeholders by advancing therapeutic options for this debilitating condition.
More about Actinogen Medical Limited
Actinogen Medical Limited is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and behavioral abnormalities associated with these diseases.
YTD Price Performance: 25.00%
Average Trading Volume: 75,000
Technical Sentiment Signal: Sell
Current Market Cap: $63.46M
Learn more about ACW stock on TipRanks’ Stock Analysis page.